The funds support the completion of clinical studies for the Tempe, Arizona-based company’s GammaTile system. That includes the ROADS clinical study evaluating GammaTile for newly diagnosed brain metastases and the GESTALT clinical trial for patients with newly diagnosed glioblastomas (GBMs).

GT Medical also plans to use funds to support the continued commercialization of GammaTile. The FDA-cleared bioresorbable radiotherapy implant treats brain tumors. GammaTile, a bioresorbable collagen tile, features embedded seeds of Cesium-131, a radioactive isotope. It delivers a high dose of radiation directly to the tumor cavity to help reduce tumor recurrence.